Overview

ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Assess safety and tolerability of ADI-PEG 20 in combination with radiotherapy and Temozolomide in newly diagnosed GBM
Phase:
Phase 1
Details
Lead Sponsor:
Polaris Group
Treatments:
Temozolomide